Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).

NCT02515838 is registered in ClinicalTrials.gov with Modus Therapeutics AB as lead sponsor.

NCT NCT02515838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02515838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).
Lead sponsor
Modus Therapeutics AB
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
May 31, 2019
Enrollment
147 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

sickle-cell disease